[DOWNLOAD] "Section V: Biomedical Sciences." by Georgia Journal of Science * Book PDF Kindle ePub Free
eBook details
- Title: Section V: Biomedical Sciences.
- Author : Georgia Journal of Science
- Release Date : January 22, 2008
- Genre: Engineering,Books,Professional & Technical,
- Pages : * pages
- Size : 166 KB
Description
PROSTATE CANCER AND CONSTITUTIVE EXPRESSION OF IMMUNOSUP PRESSIVE CYTOKINES AND CHEMOKINES, Godwin A. Ananaba* (1), K. Gordon (1), G. Ifere A. Campbell (1), E. Ekong (2), F.O. Eko (2) and J. Igietseme (3), Clark Atlanta University, Atlanta, GA 30314, Morehouse School of Medicine and Centers for Disease Control & Prevention, Atlanta, GA 30333. Cytokines and chemokines and their cognate receptors are essential immune effector molecules that are known to be involved in tumor progression. The specific cytokines and chemokines in particular are generally immunousuppressive and have been reported to be elevated in a large number of advanced tumors and correlated with poor prognosis, In this study, we investigated the hypothesis that Th2 specific cytokines IL-10, IL-4 and Th2 specific chemokine CCL-17(TARC) and cognate receptor CCR4 are significantly up-regulated in prostate adenocarcinoma cell lines relative to normal prostate epithelial cells. Standard PCR was performed using primers specific for IL-10, IL-4 and CCL-17. Preliminary results indicate that IL-10, IL-4 and CCL-17 are expressed in DU145, LNCaP and PC3 tumor cell lines. The production of Th2 specific cytokines and chemokines by prostate tumor cell lines may explain a possible mechanism for them to negatively modulate the immune response and support their metastatic potential. Cytokines and chemokines may be used as potential diagnostic biomarkers for prostate cancer disease progression. In addition, an efficacious vaccine against prostate cancer will depend on its ability to inhibit the recruitment of known distinct functional Th2 subsets implicated in prostate cancer progression. (Supported by PHS grant GM08247, GM08248, A141231). THE DEVELOPMENT OF A PROPHYLACTIC VACCINE AGAINST CHLAMYDIA TRACHOMATIS GENTIAL INFECTION **, A. Campbell*, E.Ekong (2), G.Ifere (1), T. Belay (1), E. Barr(1), F.EKo (2), J. Igietseme (2),(3) and G. Ananaba (1), (1)Clark Atlanta University, (2) Morehousee School of Medicine, (3) Centers for Disease Control & Prevention, Atlanta, GA. C. trachomatis genital infection is a prevalent bacterial sexually transmitted disease. Vaccinology strategies are attempting to produce an effective vaccine that would confer immunity against genital chlamydial infection. Our strategy is to develop of a vaccine scheme that utilizes a commensal bacteria as a live delivery vehicle of chlamydia antigens to the immune system. Lactobacilli are of the normal flora of the human genital and urinary tracts. We hypothesize that a vaccine utilizing lactobacilli as a live delivery vehicle will produce significant quantities of chlamydia antigen and induce mucosal, humoral and cell-mediated immune responses. In our laboratory, a plasmid construct DNA pGKOMP1 harboring the omp1 gene of C. trachomatis which encodes the major outer membrane protein has been achieved. We developed the recombinant plasmid using plasmid pGK12 and a multiple cloning site. By gel electrophoresis and DNA sequencing, we have confirmed the construct and verified its orientation. The expression of plasmid pGKOMP1 in Lactobacillus construct and verified its orientation. The expression of plasmid pGKOMP1 in Lactobacillus constitutes a recombinant vaccine with the potential to produce an efficacious vaccine against C. trachomatis genital infection. Our vaccine scheme can be used for vaccinology efforts towards other infectious diseases. Supported by NIH grants GM08247 and A141231.